Independent Medical Education Grant - Unmet Need and Emerging Data in Muscle Invasive Bladder Cancer (MIBC)

Registration Deadline:

Vanderbilt Contact:

  • Swapneeta Date

More Information:

Explore other Industry Opportunities:

Pfizer and Astellas collaboration offering independent medical education grants to address current gaps in the rapidly evolving MIBC treatment landscape.

Overview

  • Up to $220,000 per individual project over 18-24 months
  • Total available budget of $500,000
  • Award includes direct costs, institutional overhead (capped at 28%), and indirect costs
    United States only 
     

Priority Areas

  • Unmet needs in current MIBC treatment: Limitations with available systemic therapies
  • Antibody-drug conjugates (ADCs): Role and targeted mechanisms of action
  • Perioperative therapies: Use and impact on patient outcomes
  • Adverse event management: Optimizing management in MIBC setting
  • Multidisciplinary care: Communication and coordination between teams 

Eligibility & Requirements

  • Organizations only: medical/nursing schools, healthcare institutions, professional societies, medical education companies
  • Must be legally able to receive funding directly from Pfizer
  • Clinical research projects evaluating therapeutic efficacy will not be considered 

Timeline

  • November 12, 2025: Submission Deadline
  • December 2025: Grant Award Notification
  • February 2026: Project Start Date 

How To Submit

  • Submit via www.cybergrants.com/pfizer/knowledge
  • Upload 15-page proposal (single-spaced, Calibri 12-point font, 1-inch margins)
  • Select Primary Area: "Oncology – Genitourinary - KG" 
     

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.